EMMA — Emmaus Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $0.70m
- $30.25m
- $16.65m
- 23
- 88
- 25
- 42
Annual cashflow statement for Emmaus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1.35 | -15.9 | -10.6 | -3.73 | -6.45 |
| Depreciation | |||||
| Non-Cash Items | 0.104 | 12.5 | 3.29 | 4.82 | -0.055 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.97 | 2.11 | 2.21 | -2.62 | 4.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -2.45 | -1.25 | -5.07 | -1.5 | -2.29 |
| Capital Expenditures | -0.015 | -0.073 | -0.026 | -0.017 | -0.012 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 5.49 | -6.3 | -2.36 | -0.415 | 2.51 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 5.47 | -6.38 | -2.39 | -0.432 | 2.5 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -2.31 | 7.41 | 7.23 | 2.48 | -1.35 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.718 | -0.208 | -0.258 | 0.526 | -1.16 |